[ad_1] Shares of Biocon extended gains on Tuesday, December 24 after the United States Food and Drug Administration (USFDA) issued an Establishment Inspection Report (EIR) with a Voluntary Action Status (VAI) for its Active Pharmaceutical Ingredients (API) facility in Bengaluru. Company Value Change %Change The EIR with the VAI status was for the site 1 […]
US FDA issues four observations for Biocon’s Bengaluru API facility – CNBC TV18
[ad_1] Biotech company Biocon, on September 28, announced that the U.S. Food and Drug Administration (US FDA) has completed a surveillance inspection of its Active Pharmaceutical Ingredient (API) facility in Bengaluru. The inspection, which took place between September 23 and September 27, 2024, resulted in four observations by the regulatory body. Biocon has not disclosed […]